Stem Cell Therapies: Upcoming Opportunities in Cardiovascular and Metabolic Disorders (CVMD)
Cardiovascular disorders and metabolic disorders are considered to be amongst the leading causes of death worldwide. In fact, approximately one-third of the annual number of deaths across the globe are attributed to cardiovascular disorders. Likewise, a significant proportion of the global population suffers from diabetes or some form of metabolism related clinical condition. As per IDF Diabetes Atlas, the treatment of diabetes and related complications incurred USD 727 billion in global healthcare expenditure in 2017. Advances in cell biology and regenerative medicine have led to the development of stem cell therapies that can potentially address several unmet needs and potentially offer a cure for various cardiovascular and metabolic disorders.
I have highlighted below some of the most interesting insights from our study. You can also access additional details Stem Cell Therapy Cardiac Metabolic Disorders market.
The present treatment landscape of cardiovascular and metabolic diseases is characterized by a variety of unmet needs; stem cell therapies have emerged as a viable therapeutic option.
Opinions of industry experts and patients, expressed across numerous scientific articles and online portals, highlight the existence of several unmet needs related to the treatment of cardiovascular & metabolic disorders.
Presently, over 60 stem cell therapies are being evaluated across different phases of development for a variety of cardiovascular diseases and chronic metabolism-related disorders.
The current pipeline features a mix of autologous and allogeneic therapies; diverse routes of administration are presently being explored for the administration of such therapies

In order to achieve a competitive edge, therapy developers are increasingly focusing on conducting clinical trials across different geographies for multiple indications.
Investors have realized the potential of stem cell-based therapies in treating these disorders; over USD 2 billion has recently been raised across more than 120 funding instances

In addition, there has been a surge in partnership activity, especially R&D related deals; innovation is being driven by both industry / academic players and is evident across peer reviewed scientific literature

As multiple late stage molecules get commercialized in near future, the market for stem cell therapies for cardiovascular & metabolic disorders is poised to grow significantly.
The overall opportunity is well distributed across the various types of stem cells used, routes of administration and geographical regions.
To learn more, please click Stem Cell Therapy Cardiac Disorders. For any queries / suggestions, please do not hesitate to contact us at sales@rootsanalysis.com.
Our Social Media Platform
- Roots Analysis Twitter – https://twitter.com/RootsAnalysis
- Roots Analysis Linkedin – https://www.linkedin.com/company/roots-analysis/mycompany/
Related Posts

Cell and Gene Therapy Technology Update: ReNeuron Presents Positive Data

CARsgen anti-BCMA CAR T Therapy Receives RMAT Designation

Cell Therapy Manufacturing: A Niche but Rapidly Growing Multi-Billion Dollar Industry
About Author
Arun_Gupta
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.